MEK-4 Antibody (G-6): sc-166168
- MEK-4 Antibody (G-6) is a mouse monoclonal IgG2b κ, cited in 3 publications, provided at 200 µg/ml
- raised against amino acids 302-399 mapping at the C-terminus of MEK-4 of human origin
- recommended for detection of MEK-4 of mouse, rat and human origin by WB, IP, IF, IHC(P) and ELISA; also reactive with additional species, including bovine
- m-IgG2b BP-HRP is the preferred secondary detection reagent for MEK-4 Antibody (G-6) for WB and IHC(P) applications. This reagent is now offered in a bundle with MEK-4 Antibody (G-6) (see ordering information below).
MEK-4 Antibody (G-6) is a mouse monoclonal IgG2b antibody that detects MEK-4 in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). MEK-4, also known as MKK-4, plays a crucial role in the mitogen-activated protein kinase (MAPK) signaling pathway by specifically activating both p38 and c-Jun N-terminal kinase (JNK) MAP kinases, which are essential for cellular responses to stress, inflammation, and apoptosis. The activation of these kinases is vital for regulating various physiological processes, including cell differentiation, proliferation, and survival, making MEK-4 a significant player in cellular signaling networks. Understanding MEK-4 function and interactions within the MAPK pathway can provide insights into the mechanisms underlying various diseases, including cancer and neurodegenerative disorders. Anti-MEK-4 antibody (G-6) is an invaluable tool for researchers aiming to explore the complexities of MAPK signaling and its implications in health and disease.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
MEK-4 Antibody (G-6) References:
- Inhibition of lipopolysaccharide-stimulated NO production by a novel synthetic compound CYL-4d in RAW 264.7 macrophages involving the blockade of MEK4/JNK/AP-1 pathway. | Lin, MW., et al. 2007. Biochem Pharmacol. 73: 1796-806. PMID: 17379190
- MEK4 function, genistein treatment, and invasion of human prostate cancer cells. | Xu, L., et al. 2009. J Natl Cancer Inst. 101: 1141-55. PMID: 19638505
- Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors. | Deibler, KK., et al. 2019. ChemMedChem. 14: 615-620. PMID: 30707493
- Modeling MEK4 Kinase Inhibitors through Perturbed Electrostatic Potential Charges. | Mishra, RK., et al. 2019. J Chem Inf Model. 59: 4460-4466. PMID: 31566378
- Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma. | Kwong, AJ., et al. 2021. ACS Med Chem Lett. 12: 1559-1567. PMID: 34676038
- ACT001 inhibits pituitary tumor growth by inducing autophagic cell death via MEK4/MAPK pathway. | Cai, L., et al. 2022. Acta Pharmacol Sin. 43: 2386-2396. PMID: 35082393
- Pazopanib alleviates neuroinflammation and protects dopaminergic neurons in LPS-stimulated mouse model by inhibiting MEK4-JNK-AP-1 pathway. | Sun, HY., et al. 2023. Acta Pharmacol Sin. 44: 1135-1148. PMID: 36536076
- Overexpression of miR-92a attenuates kidney ischemia-reperfusion injury and improves kidney preservation by inhibiting MEK4/JNK1-related autophagy. | Ma, M., et al. 2023. Cell Mol Biol Lett. 28: 20. PMID: 36890442
- Butyrate protects the intestinal barrier by upregulating Fut2 expression via MEK4-JNK signaling pathway activation. | Zhang, DD., et al. 2025. Pediatr Res. 97: 128-137. PMID: 39134757
- Chromosomal localization of four MAPK signaling cascade genes: MEK1, MEK3, MEK4 and MEKK5. | Rampoldi, L., et al. 1997. Cytogenet Cell Genet. 78: 301-3. PMID: 9465908
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MEK-4 Antibody (G-6) | sc-166168 | 200 µg/ml | $322.00 | |||
MEK-4 Antibody (G-6): m-IgG2b BP-HRP Bundle | sc-548511 | 200 µg Ab; 10 µg BP | $361.00 |